» Articles » PMID: 28190087

Airway Remodeling in Asthma: What Really Matters

Overview
Journal Cell Tissue Res
Date 2017 Feb 13
PMID 28190087
Citations 159
Authors
Affiliations
Soon will be listed here.
Abstract

Airway remodeling is generally quite broadly defined as any change in composition, distribution, thickness, mass or volume and/or number of structural components observed in the airway wall of patients relative to healthy individuals. However, two types of airway remodeling should be distinguished more clearly: (1) physiological airway remodeling, which encompasses structural changes that occur regularly during normal lung development and growth leading to a normal mature airway wall or as an acute and transient response to injury and/or inflammation, which ultimately results in restoration of a normal airway structures; and (2) pathological airway remodeling, which comprises those structural alterations that occur as a result of either disturbed lung development or as a response to chronic injury and/or inflammation leading to persistently altered airway wall structures and function. This review will address a few major aspects: (1) what are reliable quantitative approaches to assess airway remodeling? (2) Are there any indications supporting the notion that airway remodeling can occur as a primary event, i.e., before any inflammatory process was initiated? (3) What is known about airway remodeling being a secondary event to inflammation? And (4), what can we learn from the different animal models ranging from invertebrate to primate models in the study of airway remodeling? Future studies are required addressing particularly pheno-/endotype-specific aspects of airway remodeling using both endotype-specific animal models and "endotyped" human asthmatics. Hopefully, novel in vivo imaging techniques will be further advanced to allow monitoring development, growth and inflammation of the airways already at a very early stage in life.

Citing Articles

An Updated Review on the Use of Noninvasive Respiratory Supports in the Management of Severe Asthma Exacerbations.

Cuttone G, La Via L, Pappalardo F, Sorbello M, Paterno D, Piattoli M Medicina (Kaunas). 2025; 61(2).

PMID: 40005443 PMC: 11857382. DOI: 10.3390/medicina61020328.


Diabetes-inducing effects of bronchial asthma.

Al-Beltagi M, Bediwy A, Saeed N, Bediwy H, Elbeltagi R World J Diabetes. 2025; 16(1):97954.

PMID: 39817208 PMC: 11718464. DOI: 10.4239/wjd.v16.i1.97954.


Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction.

Israel E, Castro M, Ambrose C, Llanos J, Molfino N, Martin N ERJ Open Res. 2024; 10(6).

PMID: 39588080 PMC: 11587167. DOI: 10.1183/23120541.00164-2024.


Unraveling heterogeneity and treatment of asthma through integrating multi-omics data.

Zhang W, Zhang Y, Li L, Chen R, Shi F Front Allergy. 2024; 5:1496392.

PMID: 39563781 PMC: 11573763. DOI: 10.3389/falgy.2024.1496392.


Biologics and airway remodeling in asthma: early, late, and potential preventive effects.

Varricchi G, Poto R, Lommatzsch M, Brusselle G, Braido F, Virchow J Allergy. 2024; 80(2):408-422.

PMID: 39520155 PMC: 11804314. DOI: 10.1111/all.16382.


References
1.
Bisgaard H, Jensen S, Bonnelykke K . Interaction between asthma and lung function growth in early life. Am J Respir Crit Care Med. 2012; 185(11):1183-9. DOI: 10.1164/rccm.201110-1922OC. View

2.
Foster P, Yang M, Herbert C, Kumar R . CD4(+) T-lymphocytes regulate airway remodeling and hyper-reactivity in a mouse model of chronic asthma. Lab Invest. 2002; 82(4):455-62. DOI: 10.1038/labinvest.3780438. View

3.
Holgate S . The sentinel role of the airway epithelium in asthma pathogenesis. Immunol Rev. 2011; 242(1):205-19. DOI: 10.1111/j.1600-065X.2011.01030.x. View

4.
Muhlfeld C, Ochs M . Quantitative microscopy of the lung: a problem-based approach. Part 2: stereological parameters and study designs in various diseases of the respiratory tract. Am J Physiol Lung Cell Mol Physiol. 2013; 305(3):L205-21. DOI: 10.1152/ajplung.00427.2012. View

5.
Temann U, Geba G, Rankin J, Flavell R . Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med. 1998; 188(7):1307-20. PMC: 2212487. DOI: 10.1084/jem.188.7.1307. View